REGENXBIO (NASDAQ:RGNX – Get Free Report) and Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.
Profitability
This table compares REGENXBIO and Anebulo Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| REGENXBIO | -110.29% | -78.29% | -34.49% |
| Anebulo Pharmaceuticals | N/A | -68.66% | -64.94% |
Analyst Ratings
This is a summary of recent ratings and target prices for REGENXBIO and Anebulo Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| REGENXBIO | 1 | 1 | 8 | 0 | 2.70 |
| Anebulo Pharmaceuticals | 1 | 1 | 0 | 0 | 1.50 |
Earnings & Valuation
This table compares REGENXBIO and Anebulo Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| REGENXBIO | $83.33 million | 4.85 | -$227.10 million | ($3.47) | -2.30 |
| Anebulo Pharmaceuticals | N/A | N/A | -$8.48 million | ($0.19) | -2.52 |
Anebulo Pharmaceuticals has lower revenue, but higher earnings than REGENXBIO. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 12.8% of REGENXBIO shares are held by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
REGENXBIO has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -0.81, indicating that its share price is 181% less volatile than the S&P 500.
Summary
REGENXBIO beats Anebulo Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About REGENXBIO
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
About Anebulo Pharmaceuticals
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.
